onc Videos

Videos

Conference Coverage

Treatment Strategies for Patients With Double Refractory Chronic Lymphocytic Leukemia

02/27/2024

Featuring Neil E. Kay, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.

At the Lymphoma, Leukemia &...

02/27/2024

Lymphoma, Leukemia & Myeloma Network

Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center

Videos

Analyzing Immunotherapy Options for the Treatment of Patients With Large-Cell Lymphoma

02/26/2024

Featuring Andrew Zelenetz, MD

Andrew Zelenetz, MD, discusses up and coming treatment developments on the horizon within the large-cell lymphoma research space, focusing on the importance of immunotherapy.

Andrew Zelenetz, MD, discusses...

02/26/2024

Oncology

Videos

R-CHOP Followed by R-ICE Treatment Shows Potential for Patients With Non-GCB DLBCL

02/26/2024

Featuring Andrew Zelenetz, MD

Andrew Zelenetz, MD, shares study results that suggest sequential rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) induction followed by rituximab, ifosfamide, carboplatin, and etoposide ([R]-ICE) consolidation...

Andrew Zelenetz, MD, shares...

02/26/2024

Oncology

Conference Coverage

Optimal Use of Bispecific Antibodies for Multiple Myeloma Treatment

02/23/2024

Featuring Ajai Chari, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, University of California – San Francisco, San Francisco, California, discusses the role of bispecific antibodies in the treatment of patients with multiple...

At the Lymphoma, Leukemia &...

02/23/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Evaluating the Potential Value of MRD as a Predictive Variable for Multiple Myeloma

02/23/2024

Featuring Ajai Chari, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, evaluates the potential value of measurable residual disease as a predictive variable for multiple myeloma.

At the Lymphoma, Leukemia &...

02/23/2024

Lymphoma, Leukemia & Myeloma Network

Videos

Capivasertib Plus Palbociclib and Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer

02/23/2024

Featuring Komal Jhaveri, MD

Komal Jhaveri, MD, discusses results from the CAPItello-291 study, which led to the FDA approval of capivasertib plus fulvestrant for HR-positive, HER2-negative, advanced breast cancer harboring one or more PIK3CA/AKT1/PTEN alterations.

Komal Jhaveri, MD, discusses...

02/23/2024

Oncology

Conference Coverage

Role of CD38 Monoclonal Antibodies and Bispecific Antibodies in Treating Multiple Myeloma

02/23/2024

Featuring Ajai Chari, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, shares his insights on the role of CD38 monoclonal antibodies and bispecific antibodies for the treatment of patients with multiple myeloma.

At the Lymphoma, Leukemia &...

02/23/2024

Lymphoma, Leukemia & Myeloma Network

Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD

Videos

Pertuzumab Plus Trastuzumab for Early-Stage HER2-Positive Breast Cancer

02/22/2024

Featuring Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD

Featuring Reshma Mahtani, DO; Terry M...

In this video, a panel of experts highlight 8-year updated results from the APHINITY trial and reflect on the progress that has been made in the setting of HER2-positive breast cancer.

In this video, a panel of...

02/22/2024

Oncology

Videos

Assessing Efficacy of Jaktinib Among Ruxolitinib-Intolerant Patients With Myelofibrosis

02/21/2024

Featuring Jie Jin, MD, PhD

Jie Jin, MD, PhD, shares results from a phase 2 study that explored the efficacy of Janus kinase inhibitor jaktinib treatment for ruxolitinib-intolerant patients with myelofibrosis.

Jie Jin, MD, PhD, shares results...

02/21/2024

Oncology

Videos

Optimizing Treatment for Patients With High-Risk HER2-Positive Breast Cancer

02/21/2024

Featuring Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD

Featuring Reshma Mahtani, DO; Terry M...

In this video, our experts explore therapy options for patients with high-risk HER2-positive breast cancer, sharing their views on anthracycline-based therapies, neratinib, and immunotherapy for these patients, and discussing data from the...

In this video, our experts...

02/21/2024

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology